Tirzepatide
Dual GIP and GLP-1 Receptor Agonist
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Available as FDA-approved Mounjaro® for Type 2 diabetes and Zepbound® for weight management and obstructive sleep apnea. It provides superior weight loss and glycemic control compared to single-pathway medications through its unique dual mechanism of action.
Complete Research Database
SURMOUNT-1
View StudyTirzepatide for Weight Reduction in Nondiabetic Adults
PRIMARY RESULTS
20.9% weight loss with 15mg dose vs 3.1% placebo
KEY FINDINGS
- •91% of participants achieved ≥5% weight loss with 15mg dose
- •57% achieved ≥20% weight loss
- •Significant improvements in cardiometabolic parameters
SURPASS-2
View StudyTirzepatide vs Semaglutide in Type 2 Diabetes
PRIMARY RESULTS
Superior glycemic control vs semaglutide (HbA1c reduction: 2.24% vs 1.86%)
KEY FINDINGS
- •Greater HbA1c reduction compared to semaglutide
- •Superior weight loss (11.2kg vs 5.7kg)
- •Better achievement of composite endpoints
Medical Disclaimer
Tirzepatide is FDA-approved as Mounjaro® for Type 2 diabetes and Zepbound® for chronic weight management. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.